In a trial with 548 participants, showed significant improvements in metabolic parameters associated with bodyweight loss in individuals with type 2 diabetes.
Greater bodyweight loss correlated with improvements in metabolic parameters.
Weak but significant correlations were observed between bodyweight changes and triglycerides, high-density lipoprotein cholesterol, and systolic blood pressure.
Weight loss was linked to treatment differences between tirzepatide and dulaglutide 0.75 mg across various metabolic parameters.
Fasting serum glucose showed the lowest association with bodyweight loss among the metabolic improvements.
Simplified
AIMS/INTRODUCTION: In the SURPASS J-mono trial, demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes. This post hoc analysis evaluated the potential relationships between weight loss and metabolic improvements in SURPASS J-mono.
MATERIALS AND METHODS: Metabolic parameter data from tirzepatide-treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived. Mediation analyses were conducted to evaluate weight loss-associated and -unassociated effects of tirzepatide vs dulaglutide 0.75 mg.
RESULTS: This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137). Weight loss subgroups showed greater improvement in metabolic parameters with greater bodyweight loss. Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18-0.25), high-density lipoprotein cholesterol (r = -0.37 to -0.29), and systolic blood pressure (r = 0.19-0.41) were observed across treatment groups; in diastolic blood pressure in the tirzepatide 5-mg (r = 0.28), pooled tirzepatide (r = 0.20), and dulaglutide 0.75-mg (r = 0.23) groups; and in fasting serum glucose in the dulaglutide 0.75-mg (r = 0.18) and pooled tirzepatide (r = 0.13) groups. Weight loss was associated with treatment differences between tirzepatide and dulaglutide 0.75 mg to varying degrees across metabolic parameters, with improvements in fasting serum glucose having the lowest association with weight loss (36.6%-43.5%).
CONCLUSIONS: In this post hoc analysis, non-glycemic and glycemic parameter improvements appeared differentially associated with weight loss, suggesting both weight loss-associated and -unassociated effects of tirzepatide.
Key numbers
-0.37 to -0.29
Correlation with Improvement
Pearson correlation coefficients for across treatment groups.
36.6% to 43.5%
Improvement Contribution
Percentage of treatment difference attributed to weight loss.
Full Text
We can’t show the full text here under this license.
